LENZ Signs an Exclusive License Agreement with Ji Xing for LNZ100 ( aceclidine) and LNZ101 (aceclidine + brimonidine) to Treat Presbyopia in Greater China
Presbyopia Physician - Differentiating Miotics for Pharmacological Management of Presbyopia
LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies | Business Wire